HLA-DR Antibody (6A96): sc-71260
- HLA-DR Antibody (6A96) is a mouse monoclonal IgG2b κ provided at 200 µg/ml
- raised against activated peripheral blood mononuclear cells of human origin
- recommended for detection of HLA-DR of mouse, rat and human origin by WB, IP and FCM
- See HLA-DR (520B): sc-69673 for HLA-DR antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG2b BP-HRP is the preferred secondary detection reagent for HLA-DR Antibody (6A96) for WB applications. This reagent is now offered in a bundle with HLA-DR Antibody (6A96) (see ordering information below).
HLA-DR Antibody (6A96) is a mouse monoclonal IgG2b kappa light chain antibody, designed to recognize the HLA-DR protein, also known as Human Leukocyte Antigen-DR or MHC class II DR isotype. HLA-DR monoclonal antibody (6A96) is raised against activated peripheral blood mononuclear cells of human origin and exhibits strong reactivity with HLA-DR proteins from human, mouse, and rat species, making HLA-DR (6A96) antibody ideal for applications such as western blotting (WB), immunoprecipitation (IP), and flow cytometry (FCM). HLA-DR protein is a crucial component of the immune system, functioning as an α/β heterodimer that presents exogenous peptides to CD4+ helper T cells, thereby initiating and regulating adaptive immune responses. Structurally, HLA-DR interacts with several key proteins, including HLA-DM, which facilitates peptide loading and editing, and the invariant chain (Ii), which stabilizes the MHC class II molecule during transport through the endosomal pathway. These interactions are essential for proper antigen presentation and subsequent T cell activation, underscoring the importance of post-translational modifications such as glycosylation in maintaining HLA-DR′s functionality and stability. Additionally, HLA-DR engages with CD4 receptors on T cells, enabling precise immune regulation and response. HLA-DR (6A96) monoclonal antibody is an indispensable tool for researchers investigating immune mechanisms, autoimmune diseases, and the development of therapeutic antibodies, providing reliable detection and analysis of HLA-DR interactions in various experimental settings.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
HLA-DR Antibody (6A96) References:
- Sputum eosinophils from asthmatics express ICAM-1 and HLA-DR. | Hansel, TT., et al. 1991. Clin Exp Immunol. 86: 271-7. PMID: 1682072
- HLA-DR and tuberculin tests in rheumatoid arthritis and tuberculosis. | Bahr, GM., et al. 1989. Ann Rheum Dis. 48: 63-8. PMID: 2784308
- HLA-DR antigen detection in giant cell lesions. | Regezi, JA., et al. 1986. J Oral Pathol. 15: 434-8. PMID: 3100742
- The quantitation of HLA-DR expression on human cells using immunocytochemistry. | Poulter, LW., et al. 1987. J Immunol Methods. 98: 227-34. PMID: 3553331
- HLA-DR antigen linkage in hypertrophic cardiomyopathy. | Becque, O., et al. 1981. Am Heart J. 102: 806-8. PMID: 6945040
- Membrane insertion and oligomeric assembly of HLA-DR histocompatibility antigens. | Kvist, S., et al. 1982. Cell. 29: 61-9. PMID: 6955026
- HLA-DR antigens and ankylosing spondylitis. | Dejelo, CL., et al. 1978. Transplant Proc. 10: 971-2. PMID: 734749
- The expression of HLA-DR antigen in cervical neoplasia. | Raju, GC., et al. 1994. Cancer Detect Prev. 18: 367-73. PMID: 7812983
- HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. | Berlin, M., et al. 1997. Am J Respir Crit Care Med. 156: 1601-5. PMID: 9372682
- Peptide loading onto recycling HLA-DR molecules occurs in early endosomes. | Pinet, VM. and Long, EO. 1998. Eur J Immunol. 28: 799-804. PMID: 9541573
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HLA-DR Antibody (6A96) | sc-71260 | 200 µg/ml | $316.00 | |||
HLA-DR Antibody (6A96): m-IgG2b BP-HRP Bundle | sc-548449 | 200 µg Ab; 10 µg BP | $354.00 |